Home Featured Page 288

Featured

Latest

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke

Nova Mentis Appoints Gary R. Harlem to Scientific Advisory Board

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds...

Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor

Study: 69% of Suicidal Patients Saw ‘Significant’ Improvement With Ketamine Therapy

War Hero from Ontario Featured in Psychedelic Documentary

Should Montreal Expect Psychedelic Revolution in the Near Future? Activists Think...

Connecticut, Florida Legislators File Psychedelic Mushroom Bills

1...287288289...296 Page 288 of 296

EDITOR PICKS

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56 President Talks Psychedelics; Compass’ PTSD Study Published; Cybin Ousts Drysdale

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke

Nova Mentis Appoints Gary R. Harlem to Scientific Advisory Board

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds...

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds...

Tryp Therapeutics Appoints Dr. Joel Castellanos as Clinical Advisor

Study: 69% of Suicidal Patients Saw ‘Significant’ Improvement With Ketamine Therapy

The Plant Spirit Summit

War Hero from Ontario Featured in Psychedelic Documentary

Should Montreal Expect Psychedelic Revolution in the Near Future? Activists Think...

Connecticut, Florida Legislators File Psychedelic Mushroom Bills

EDITOR PICKS

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Pα+ Psychedelic Bulletin #208: Psychedelic CEOs’ FDA Wish-List; APA Division 56...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY